BBVA USA Bancshares Inc. Sells 692 Shares of Eli Lilly and Company (NYSE:LLY)

BBVA USA Bancshares Inc. lessened its stake in Eli Lilly and Company (NYSE:LLY) by 5.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,825 shares of the company’s stock after selling 692 shares during the period. BBVA USA Bancshares Inc.’s holdings in Eli Lilly and were worth $2,035,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of LLY. Old North State Trust LLC grew its holdings in Eli Lilly and by 1.2% in the second quarter. Old North State Trust LLC now owns 5,660 shares of the company’s stock worth $929,000 after purchasing an additional 66 shares during the period. Endurance Wealth Management Inc. grew its holdings in Eli Lilly and by 1.6% in the second quarter. Endurance Wealth Management Inc. now owns 4,141 shares of the company’s stock worth $680,000 after purchasing an additional 66 shares during the period. Parcion Private Wealth LLC grew its holdings in Eli Lilly and by 3.5% in the second quarter. Parcion Private Wealth LLC now owns 1,929 shares of the company’s stock worth $322,000 after purchasing an additional 66 shares during the period. DC Investments Management LLC grew its holdings in Eli Lilly and by 1.3% in the second quarter. DC Investments Management LLC now owns 5,186 shares of the company’s stock worth $851,000 after purchasing an additional 66 shares during the period. Finally, StoneX Group Inc. grew its holdings in Eli Lilly and by 1.3% in the second quarter. StoneX Group Inc. now owns 4,958 shares of the company’s stock worth $814,000 after purchasing an additional 66 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

A number of research firms have commented on LLY. Truist began coverage on shares of Eli Lilly and in a report on Friday, October 23rd. They issued a “buy” rating and a $180.00 price target for the company. Berenberg Bank began coverage on shares of Eli Lilly and in a report on Tuesday, September 29th. They set a “hold” rating and a $144.00 price objective for the company. Morgan Stanley reduced their price objective on shares of Eli Lilly and from $176.00 to $170.00 and set an “overweight” rating for the company in a report on Wednesday. ValuEngine cut shares of Eli Lilly and from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, October 16th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $169.93.

Eli Lilly and stock opened at $132.55 on Friday. Eli Lilly and Company has a fifty-two week low of $110.51 and a fifty-two week high of $170.75. The stock has a market cap of $126.78 billion, a PE ratio of 21.52, a price-to-earnings-growth ratio of 1.25 and a beta of 0.19. The firm’s 50-day simple moving average is $147.67 and its 200 day simple moving average is $153.45. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.94 and a current ratio of 1.22.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Sunday, November 1st. The company reported $1.54 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.17). Eli Lilly and had a return on equity of 183.80% and a net margin of 24.48%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.87 billion. During the same quarter last year, the firm posted $1.48 earnings per share. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 7.28 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a $0.74 dividend. This represents a $2.96 annualized dividend and a yield of 2.23%. The ex-dividend date of this dividend is Thursday, November 12th. Eli Lilly and’s dividend payout ratio is 49.01%.

In other Eli Lilly and news, SVP Melissa S. Barnes sold 5,000 shares of Eli Lilly and stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $151.01, for a total value of $755,050.00. Following the sale, the senior vice president now owns 23,580 shares of the company’s stock, valued at $3,560,815.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.09% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.

See Also: Understanding Relative Strength Index

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.